Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Psilocybine,Imipramine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Wesana Health Announces New Findings Indicating Psilocybin Potentiates Impact of an Anti-Depressant
Details : Results of the study showed that administration of imipramine given three weeks following a psilocybin loading dose provided an additional 39% further improvement in depressive behaviors from that of psilocybin loading dose alone.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
March 22, 2022
Lead Product(s) : Psilocybine,Imipramine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Imipramine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioequivalency Study of Imipramine Pamoate 75 mg Capsules Under Fasted Conditions
Details : Imipramine is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Depression.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 20, 2010
Lead Product(s) : Imipramine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Imipramine
Therapeutic Area : Neurology
Study Phase : Phase IV
Sponsor : Pfizer Inc | Takeda Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Imipramine and Pregabalin Combination in Painful Polyneuropathy
Details : Imipramine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Polyneuropathies.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 13, 2010
Lead Product(s) : Imipramine
Therapeutic Area : Neurology
Highest Development Status : Phase IV
Sponsor : Pfizer Inc | Takeda Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable